Stocktoria
NewAmsterdam Pharma Co N.V. NAMS
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2022-11-23
NewAmsterdam Pharma Co N.V. financials (annual)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $22.5M | $45.6M | $14.1M | $102.7M |
| R&D expense | $141.8M | $151.4M | $159.4M | $86.7M |
| SG&A expense | $106.4M | $70.4M | $37.6M | $19.5M |
| Operating income | -$225.7M | -$176.3M | -$183.0M | -$3.6M |
| Interest expense | — | — | — | $287,000 |
| Income tax | — | -$1,000 | $27,000 | — |
| Net income | -$203.8M | -$241.6M | -$176.9M | -$22.6M |
| EPS (diluted) | $-1.72 | $-2.56 | $-2.15 | $-1.19 |
| Operating cash flow | -$147.8M | -$158.6M | -$141.2M | $10.7M |
| Cash & equivalents | $490.0M | $771.7M | $340.4M | — |
| Total assets | $769.3M | $864.6M | $347.1M | $478.5M |
| Total liabilities | $85.9M | $107.1M | $58.7M | $48.4M |
| Shareholders' equity | $683.4M | $757.5M | $288.4M | $430.1M |
Growth · year-over-year · Revenue CAGR -39.7%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | -50.6% | +223.4% | -86.3% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.